AFT signs US$18.8m deal for US licence

AFT signs US$18.8m deal for US licence
AFT managing director Hartley Atkinson says the delay in signing the deal caused the downgrade.
Staff reporters
AFT Pharmaceuticals has signed a licensing and distribution agreement with US giant Hikma Pharmaceuticals USA for its Maxigesic intravenous drip.The company said not getting the deal over the line before the end of the March is the reason why it lowered its guidance.Under the deal, AFT is entitled to up to US$18.8 million (NZ$26m) in upfront, regulatory and commercial milestone payments as well as a profit share from sales.The milestone payments include US$7.5m for certain agreed milestones with $3.6m earned after Maxigesic IV gets US approval....